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Significance Statement 
Fibroblast growth factor-23 (FGF23) has been linked to different cardiovascular diseases and 
suggested as a therapeutic target. This meta-analysis compared associations from general, non-
dialysis chronic kidney disease and dialysis populations. For myocardial infarction, stroke and heart 
failure, there were consistently higher risks among participants in the top versus bottom third of the 
FGF23 distributions. However, the size of these associations did not increase across these populations, 
despite absolute differences in FGF23 between the top and bottom thirds increasing by two orders of 
magnitude. Furthermore, associations were similar for cardiovascular mortality and non-cardiovascular 
mortality. Associations which are both non-specific and which do not exhibit an exposure-response 
relationship are inconsistent with cause and effect and suggest that targeting FGF23 alone may not 
reduce cardiovascular risk.  
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Abstract 
Background 
Fibroblast growth factor-23 (FGF23) has been associated with an increased risk of cardiovascular 
disease, but it is uncertain how associations for different types of cardiovascular disease vary by level 
of kidney function. 
Methods 
We identified prospective studies reporting associations between FGF23 and risk of cardiovascular 
events. Maximally adjusted risk ratios (RRs) were extracted for each outcome, scaled to a comparison 
of the top versus bottom third of the baseline FGF23 concentration, and the results aggregated.  
Results 
Depending on assay type used, median study FGF23 concentrations ranged between 43-74 RU/mL 
and 38-47 pg/mL in 17 ‘general populations’ (i.e. populations unselected for chronic kidney disease 
[CKD]); between 102-392 RU/mL in 9 populations of patients with CKD not requiring dialysis; and 
between 79-4212 RU/mL and 2526-5555 pg/mL in 8 dialysis populations. Overall, comparing patients 
in the top versus bottom third of FGF23 concentration, the summary RRs were 1.33 (95% confidence 
interval 1.12-1.58) for myocardial infarction, 1.26 (1.13-1.41) for stroke, 1.48 (1.29-1.69) for heart failure, 
1.42 (1.27-1.60) for cardiovascular mortality, and 1.70 (1.52-1.91) for all-cause mortality. The summary 
RR for non-cardiovascular mortality, calculated indirectly, was 1.52 (1.28-1.79). When studies were 
ordered by the average differences in FGF23 between top and bottom thirds, there was no evidence of 
trend in the RRs. 
Conclusion 
The presence of an association between higher FGF23 concentration and risk of both cardiovascular 
(atherosclerotic and non-atherosclerotic) and of non-cardiovascular outcomes, together with the 
absence of any “exposure-response” relationship suggest that the relationship between FGF23 and risk 
of cardiovascular disease may be non-causal.
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Introduction 
Cardiovascular disease risk increases as kidney function declines and this elevated risk is apparent 
even in early chronic kidney disease (CKD).1-3 Cardiovascular disease in people with CKD is 
characterized particularly by arterial stiffening and left ventricular hypertrophy, which becomes 
increasingly marked as CKD advances.4-6 People with CKD are also at increased risk of atherosclerotic 
heart disease. It has been suggested that some of the excess cardiovascular risk in CKD may be 
mediated through disordered calcium-phosphate metabolism due to reduced kidney function.7-9  
 
Blood fibroblast growth factor-23 (FGF23) concentration rises early in CKD, and increases exponentially 
in relation to estimated glomerular filtration rate, functioning to maintain phosphate homeostasis as the 
capacity for urinary phosphate excretion declines.10 FGF23 possesses an atypical heparin-binding 
domain which results in a low binding affinity to most FGF receptors.11 Its physiological actions may 
therefore be limited to the parathyroid glands and kidney where its co-receptor Klotho is abundantly 
expressed. In the kidney, FGF23 downregulates renal proximal tubular sodium-phosphate co-transport 
function enhancing urinary phosphate excretion and reduces vitamin D 1-alpha hydroxylation leading 
to less intestinal calcium and phosphate absorption.12 However, FGF23 could have Klotho-independent 
actions in other tissues, including the heart,13 and may contribute to the etiology of structural heart 
disease in patients with CKD.14,15 If so, interventions targeting FGF23 might hold therapeutic potential. 
 
We conducted a systematic review and meta-analysis of the evidence from prospective studies for 
associations between FGF23 and the risk of different cardiovascular diseases. We compared the 
evidence for associations among cohorts of people unselected for CKD (‘general population’ cohorts) 
with those in patients with CKD who were not receiving dialysis at the time of recruitment (‘non-dialysed’ 
CKD cohorts) and in dialysis patients. We assessed for evidence of an “exposure-response” relationship 
both within and across each of these 3 separate populations. 
 
Methods 
Search strategy/selection strategy 
A systematic and comprehensive search for English language publications with mention of FGF23 or 
equivalent terms was performed in MEDLINE (1948-April 2017) and EMBASE (1974-April 2017, see 
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Webtable 1 for terms). Abstracts were reviewed and cohort studies in adults were selected for inclusion 
in the meta-analysis if: (i) FGF23 was a key exposure of interest; (ii) at least one clinical cardiovascular 
disease outcome was assessed, and (iii) outcomes were ascertained prospectively. Cardiovascular 
outcomes of interest included myocardial infarction, stroke, heart failure and peripheral arterial disease 
as well as mortality attributed to cardiovascular disease. Full-texts of publications which appeared to 
meet inclusion criteria were reviewed. Duplicate studies and those that included less than 200 
participants were excluded. The quality of remaining studies was assessed using the Newcastle-Ottawa 
scale16 and studies excluded if their results were at moderate-to-high risk of bias (score of <6/9). A 
study of terminal heart failure was excluded post-hoc as the population was at exceedingly high risk. 
 
Data extraction 
Three authors (AM/KD/CR) extracted the following data from full-text articles: study and study 
population characteristics, FGF23 assay type (C-terminal, reported in RU/mL, or intact, reported in 
pg/mL), measures of FGF23 distribution, details of statistical models, covariates used for multivariate 
adjustments, follow-up duration, and hazard ratios/risk ratios (RRs) for relevant cardiovascular 
outcomes for all reported models, and where reported, all-cause and cardiovascular mortality. Where 
necessary, further data were requested from study investigators. 
 
Statistics 
To assess the FGF23 associations across the wide range of FGF23 concentrations encountered in 
different populations, meta-analysis was pre-specified to be performed overall and within three study 
population types: (i) general population (i.e. unselected individuals), (ii) non-dialysed CKD (defined as 
an estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m2), and (iii) dialysis patient cohorts. 
 
For each study, we aimed to extract from the primary publication, for each outcome, the hazard ratio or 
RR yielded by the model that included the greatest number of covariates. These covariates included 
incrementally: basic demographics (+); cardiovascular risk factors (including diabetes, body-mass index 
and smoking (++); kidney function (+++); and markers of CKD-mineral bone disorder (++++). On 
account of the usually skewed nature of FGF23 distributions, studies reported associations for top 
versus bottom quintiles, quartiles or thirds of the FGF23 distribution, or less frequently, per standard 
6 
 
deviation or a unit increase in log-transformed FGF23. To enable comparisons and synthesis of data 
across the studies, these associations were converted (where necessary) to a measure of association 
corresponding to the top versus bottom third of the baseline FGF23 concentration using established 
methods (see Supplementary methods and Webtable 2 for more detail).17,18 Where non-cardiovascular 
mortality was not reported, RRs were derived indirectly from cardiovascular and all-cause mortality 
results assuming that on the natural logarithm scale, the RR for all-cause mortality is an inverse-
variance weighted average of the RRs for cardiovascular and non-cardiovascular mortality. 
 
The heterogeneity between studies (both within each population and overall) was summarized. 
Random-effects meta-analytical methods (DerSimonian and Laird)19 were used to combine the RRs for 
the top versus bottom third of baseline FGF23 concentration in each study, yielding a summary RR for 
all studies. 
 
As the median baseline FGF23 concentration correlated strongly with interquartile range, standard tests 
for linear trend (on a log scale) across studies ordered by median (or, if not reported, mean) baseline 
FGF23 concentration (within each population and across all the individual studies) were used to assess 
whether larger absolute differences in FGF23 concentration between top and bottom third were 
associated with larger RRs. Trend tests were also performed across population-specific summary RRs 
following meta-analysis of RRs from the contributing studies. In sensitivity analyses, to allow for 
potentially different relationships in dialysis populations, the trend tests across individual studies were 
repeated after excluding dialysis patient studies. 
  
Primary analyses of disease associations did not take account of whether studies employed C-terminal 
or intact assays, which is equivalent to the assumption that the results between the two assays are 
approximately comparable. However, this assumption may not necessarily hold as, for example, intra-
person biological variability of intact FGF23 may be higher than C-terminal FGF23.20 To investigate the 
sensitivity of results to this assumption, analyses were performed repeating trend tests, firstly after 
converting intact FGF23 concentration to an approximately equivalent C-terminal concentration using 
a formula developed from a small healthy general population: iFGF23=0.110*cFGF23+32.2,21 and, 
secondly, after excluding all studies that only reported intact FGF23. To further assess whether 
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associations in individual studies could have been affected by within-person FGF23 variability, 
regression dilution ratios were calculated from individual studies which had repeat FGF23 
measurements22-24 using McMahon’s non-parametric quintile method.25 RRs for cardiovascular and 
non-cardiovascular outcomes were compared by heterogeneity tests.26 Analyses were performed using 
R version 3.2.1 (www.R-project.org) using the “metafor” package v1. 
 
Results 
Our literature search (Webtable 1) identified 2477 abstracts of which 45 met the inclusion criteria (Figure 
1). Three studies were excluded after a standard assessment for bias (Webtable 3).27-29 Eight studies 
reported associations which could not be extracted or reliably expressed as RRs comparing the top 
versus bottom third of baseline FGF23 concentration30-37 (see Webtable 4 for results from these and 
the other excluded studies). Of 34 studies included in primary analyses, 17 were a predominantly 
general population cohort,22,38-53 9 were in patients with CKD not on dialysis,23, 54-61 and 8 in dialysis 
populations24,62-68 (Figure 1). For dialysis patients, a single large trial (EValuation Of Cinacalcet HCl 
Therapy to Lower CardioVascular Events [EVOLVE], n=2985) provided all the data on myocardial 
infarction, stroke, and heart failure (outcomes which were all confirmed by clinician adjudicators).24  
 
Table 1 describes the characteristics of included studies. Most of the studies (26/34) measured FGF23 
concentrations in RU/mL using a C-terminal based assay, with the remainder (8/34) in pg/mL by an 
intact assay. Measures (median or, if unavailable, mean) of FGF23 concentration were lowest in general 
population cohorts (between 43-74 RU/mL and 38-47 pg/mL for the respective assays); were higher in 
non-dialysed CKD (102-392 RU/mL), and substantially higher in dialysis patients (79-4212 RU/mL and 
2526-5555 pg/mL: Table 1).  
 
Across these three populations, the estimated absolute difference in mean FGF23 concentrations 
between the top versus bottom third of the FGF23 distributions ranged from 72 RU/mL in general 
population studies, through 433 RU/mL in non-dialysed CKD, to 8644 RU/mL in dialysis populations (C-
terminal based studies only). 
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It was notable that the 10 general population cohorts had a mean age of 65 years or above (Table 1). 
The estimated crude mortality rates were on average high in all populations, with evidence of higher 
mortality with reduced kidney function. For example, the average all-cause mortality ranged from 1.9%-
5.3% per annum (p.a.) across the general populations; 2.0%-14.2% p.a. in non-dialysed CKD; and 
2.0%-21.0% p.a. in dialysis populations. 
 
Association between FGF23 and risk of cardiovascular events 
Six studies assessed the association between FGF23 and risk of myocardial infarction (3 in general 
populations,22,44,49 2 in non-dialysed patients with CKD,44,56 and 1 in dialysis patients24). Overall, 
comparing patients in the top versus bottom third of baseline FGF23 concentration, there was a 33% 
increased risk of myocardial infarction (summary RR 1.33, 95% confidence interval 1.12-1.58), but no 
evidence of linear trend across the different patient populations studied (trend p=0.32: Figure 2).  
 
For the studies reporting an interquartile range of baseline FGF23 concentrations, there was good 
correlation between median baseline FGF23 concentration and the interquartile range (correlation 
coefficient=0.99), so ordering studies by increasing baseline FGF23 concentration effectively orders the 
studies by increasing absolute difference between the means of FGF23 concentrations in the top versus 
bottom third of each study’s FGF23 distribution. Tests for linear trend in the RRs for myocardial 
infarction across the ordered studies were non-significant both within the 3 separate populations and 
across all individual studies (trend across all individual studies p=0.22: Webfigure 1). 
 
Associations between FGF23 and risk of stroke of any type were reported in 9 studies, including 6 in 
general populations,22,44,45,48,49,52 2 in non-dialysed CKD,44,56 and 1 in dialysis patients.24 Overall, 
comparing patients in the top versus the bottom third of baseline FGF23 concentration, there was a 
26% increased risk of stroke (1.26, 1.13-1.41). This increase in risk was consistent between populations 
(trend p=0.17: Figure 2), and there was no significant trend towards larger RRs with higher median 
FGF23 difference both within each population considered separately (where relevant) and across all 
studies (trend across all individual studies p=0.95: Webfigure 2). 
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Four general population studies (n=1251 events)22,45,48,52 and a small non-dialysed CKD study (n=43 
events)56 reported ischemic stroke events. Overall, no significant association between FGF23 and risk 
of ischemic stroke was observed for the top versus the bottom third of baseline FGF concentration 
(1.08, 0.92-1.27: Webfigure 3). 
 
Associations between FGF23 and risk of heart failure were reported in 10 studies, including 5 in a 
general population,42,44-46,49 4 in patients with non-dialysed CKD,23,44,58,59 and 1 in dialysis patients.24 
Overall, comparing patients in the top versus the bottom third of baseline FGF23 concentration, there 
was a 48% increased risk of heart failure (1.48, 1.29–1.69). There was no evidence of trend across 
populations (trend p=0.89; Figure 2) and no clear trend towards larger RRs with higher median FGF23 
difference both within each population considered separately and overall (trend across all individual 
studies p=0.76: Webfigure 4). There was also no good evidence that FGF23 was more strongly 
associated with heart failure than myocardial infarction or stroke, overall (heterogeneity p=0.23) or in 
any of the 3 separate populations (Figure 2). 
 
Associations between FGF23 and risk of peripheral artery disease and some other noted cardiovascular 
outcomes are provided in Webtable 5. 
 
Association between FGF23 and mortality 
Twenty-three studies reported associations between FGF23 and all-cause mortality: 7 in a general 
population,39,40,44,47,49,51,53, 8 in non-dialysed CKD,23,44,54,56,57,59-61 and 8 in a dialysis population24,62-68. 
Overall, comparing patients in the top versus bottom third of baseline FGF23 concentration, there was 
an increased risk of death from all causes (RR 1.70, 1.52-1.91). There was no good evidence of a trend 
across the 3 populations (trend p=0.76; Figure 3) or towards larger RRs with higher median FGF23 at 
baseline (trend across all individual studies p=0.97: Webfigure 5). 
 
Eleven studies reported associations between FGF23 level and cardiovascular mortality (7 studies in 
general populations,39,40,44,46,47,51,53 2 in non-dialysed CKD,44,54and 2 in dialysis patients24,68). Overall, 
comparing patients in the top versus bottom third of the baseline FGF23 concentration, there was a 
42% increased risk of cardiovascular mortality (1.42, 1.27-1.60) with no evidence of trend across 
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populations (trend p=0.53: Figure 3) and no trend towards larger RRs with higher median FGF23 (trend 
across all individual studies p=0.49: Webfigure 6). 
 
Among dialysis patients in EVOLVE,24 comparing patients in the top versus the bottom third of the 
baseline FGF23 concentration, there was a 27% (1.27, 1.02-1.58) increased risk of non-cardiovascular 
mortality (n=514 deaths), which was similar to RR for cardiovascular mortality in this trial (1.26, 1.00-
1.57, n=607 deaths). Only 1 of the other 9 studies (a general population cohort) reported RRs for 
cardiovascular mortality (1.76, 1.34-2.32, n=474) as well as for non-cardiovascular mortality (1.47, 1.17-
1.85, n=612 deaths).53 For the remaining 8 studies RRs for non-cardiovascular mortality were derived 
indirectly using associations for cardiovascular and all-cause mortality.39,40,44,46,47,51,54,68 The overall 
combined RRs for all studies for non-cardiovascular mortality for the top versus the bottom third of the 
baseline FGF23 concentration was 1.52 (1.28-1.79) with results suggesting that, for each of the 
separate populations, the RRs for cardiovascular and non-cardiovascular mortality were comparable 
(Figure 4). 
 
Sensitivity analyses and assessment for publication bias 
The results of trend tests remained non-significant after exclusion of studies in dialysis patients 
(Webfigures 1,2,4-6), after exclusion of studies which only reported intact FGF23 concentrations, and 
after using a formula for inter-assay conversion.21 Repeat measurements within groups of FGF23 were 
highly correlated in all 3 types of populations studied (regression dilution ratios all >0.8, Webtable 6),22-
24 so adjustment for regression-dilution bias was not performed. All-cause and cardiovascular mortality 
associations were not substantially affected by adjustment for other markers of CKD-mineral bone 
disease (Webfigure 7).40,46,49,54,55,59,66 
 
Funnel plots of associations between FGF23 and all-cause mortality by type of population suggested 
evidence for publication bias for the general population cohorts (Egger regression test p=0.005) and 
that RRs for all-cause mortality may be slight overestimates (Webfigures 5&8). There was no important 
heterogeneity between studies with respect to other outcomes (Webfigures 1-4&6). 
 
Discussion 
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This systematic review and meta-analysis assessed the epidemiological associations between FGF23 
concentration and cardiovascular outcomes, as well as associations with cardiovascular and all-cause 
mortality in populations with and without known kidney disease. Overall, we found that, irrespective of 
a population’s level of kidney function, a difference in FGF23 concentration corresponding to that 
between top and bottom thirds of baseline FGF23 concentration was associated with about 30% 
increased risk of myocardial infarction and stroke, 40% increased risk of cardiovascular mortality and 
50% increased risk of heart failure. In the studies where it was possible to estimated effects on both 
cardiovascular and non-cardiovascular mortality, we found that the strength of the association between 
FGF23 and these categories of deaths was approximately similar. 
 
Bradford Hill’s criteria for causality of a disease risk factor include the presence of epidemiological 
associations which are both consistent and specific for that disease, evidence of a biological gradient 
(i.e. greater exposure leads to increased effect, which we refer to as exposure-response), temporality 
(i.e. the cause precedes the effect), and biological plausibility.69  
 
In support of raised FGF23 being a cause of cardiovascular disease, our study found consistent 
moderate associations between FGF23 and disease risks. FGF23 concentration also rises before any 
other marker of CKD-mineral bone disease,10 so it temporally mirrors the rise in cardiovascular risk as 
CKD progresses.1 In addition, there is biological plausibility since cardiac myocytes exposed to FGF23 
become hypertrophied and develop electrophysiological disturbances (sometimes referred to as “off-
target” effects as they appear to be Klotho-independent).13,14,15  
 
We also observed that FGF23 was strongly associated with non-cardiovascular causes of death, 
reflecting a lack of specificity of the associations between raised FGF23 and disease risk. This 
observation could reflect pleiotropy of FGF23 in disease causation. It has previously been reported that 
raised FGF23 is associated with a higher risk of: end-stage kidney disease,55 acute kidney injury (RR 
for top versus bottom quartile 1.99, 1.04-3.80),70 fractures (RR 1.56, 1.11-2.20),71 and serious infection 
(RR 1.59, 1.14-2.22).62 There is emerging evidence that FGF23 may promote inflammation through 
direct effects on hepatocytes,72 and predispose to infection through downregulation of monocytic 
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expression of 1,25 dihydroxycholecalciferol73 or other effects.74 A mechanistic study has also suggested 
FGF23 may promote progression of prostate cancer.75  
 
An alternative, more plausible, explanation for the observed non-specificity of associations across a 
range of disease outcomes is residual confounding. This may arise because of imprecise or incomplete 
measurement of baseline prognostic factors other than FGF23. Examples of such factors include level 
of kidney function (which is measured with greater error at high eGFR), duration of CKD, and risk factors 
which correlate with low kidney function.  
 
Furthermore, we found no evidence for a log-linear exposure-response relationship such as that which 
is commonly observed for known causes of cardiovascular disease (e.g. LDL cholesterol76,77 and blood 
pressure78). Indeed, the RRs corresponding to a difference between top and bottom thirds of FGF23 
distribution were of similar magnitude in each of the three populations despite the absolute difference 
in FGF23 varying by two orders of magnitude across these populations. Such a pattern could potentially 
be explained by a ‘log-log’ relationship with flattening of the exposure-response curve at high FGF23 
concentration. But this would imply that, if FGF23 is a cause of cardiovascular disease, therapeutic 
agents designed to reduce FGF23 would need to achieve large absolute reductions in FGF23 in those 
with high levels in order to achieve worthwhile risk reductions.  
 
A limitation of this meta-analysis is that we were, for the most part, restricted to published summary 
data. The availability of individual participant level data from all eligible studies could allow for more 
granular estimation of associations and perhaps a more sensitive analysis of any exposure-response 
relationship using a standardized method with fewer assumptions. It would also allow for the inclusion 
of the studies which could not be reliably converted onto a top versus bottom thirds scale. However, the 
studies excluded due to inability convert associations showed positive associations between FGF23 
and disease risks which were similar in size to those observed by the included studies (Webtable 4).30-
37 Furthermore, given the lack of trends across the 3 population types despite a two-fold increase in the 
absolute difference in FGF23 concentration, it is unlikely that individual participant data would identify 
an important log-linear trend missed by our tabular meta-analysis. Individual participant level data would 
also not overcome residual confounding, which is the main limitation of this meta-analysis. Finally, not 
13 
 
all relevant studies reported associations for all outcomes of interest (which may have introduced bias) 
and there was a lack of detailed data on non-cardiovascular causes of death, so it was not possible to 
examine whether there were deaths (e.g. from cancer) that were particularly strongly associated with 
FGF23. 
 
In summary, this systematic review and meta-analysis has demonstrated that across a wide range of 
levels of kidney function, higher FGF23 concentration was consistently associated with modest 
increased risks of myocardial infarction, heart failure, stroke and cardiovascular death. However, higher 
FGF23 was also associated with an increased risk of non-cardiovascular causes of death. Our findings 
suggest that associations between FGF23 and particular diseases, both in populations with CKD and 
those without known disease, may not signify cause and effect. 
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Table 1: Study and participant characteristics by population type 1 
Publication 
author + 
year/study 
acronymRef 
Study location Number 
participants/ 
follow-up duration 
Baseline 
demographics 
Baseline  
co-morbidity 
prevalences 
FGF23 assay type/ 
average FGF23 concentration 
General population studies 
Arnlov 201239 
 
ULSAM 
Uppsala, 
Sweden 
727 
Median: 9.7 years 
(range: 0.3-12.9) 
Age: 78  
Male: 100% 
 
DM: 13% 
eGFR: 74 (17) 
CVD: 27% 
Intact 
Median: 44 pg/mL (range 9–162) 
Arnlov 201338 
 
PIVUS 
Uppsala, 
Sweden 
1003  
Median: 5.1 years 
(range: 4.8-5.8) 
Age: 70  
Male: 50% 
White: 100% 
DM: 12% 
eGFR: 80 (14) 
CVD: 16% 
Intact 
Mean: 47 pg/mL (SD 24) 
Brandenburg 
201440 
 
LURIC 
Germany 2974  
Median: 9.9 years 
Age: 63 (10) 
Male: 69% 
White: 100% 
DM: 40% 
eGFR <60: 14% 
CAD: 78% 
C-terminal 
Median: 54 RU/mL (IQR 40-78) 
Deo 201541 
 
CHS 
USA 3244 
Mean: 8.1 years  
(SD 3.2) 
Age: 78 (5) 
Male: 40% 
Black: 16%  
DM: 15% 
eGFR: 71 (19) 
HF: 9%/ MI: 11% 
C-terminal 
Median: 70 RU/mL (IQR 53-99) 
di Giuseppe 201442 
 
EPIC-Potsdam 
Germany 1443 
Mean 8 years  
(SD 2.2) 
Age: 52 
Male: 44% 
White: NR 
DM: 7% 
eGFR: NR 
CHD: 10.8% 
C-terminal 
Median: 48 RU/mL (IQR NR) 
di Giuseppe 201522 
 
EPIC-Germany 
Germany 2908 
Mean: 8.2 years 
Age: 52 
Male: 50% 
White: NR 
DM: 6% 
eGFR: 108 
Excluded MI & ST 
C-terminal  
Median: 54 RU/ml (IQR 38-72)* 
 
Garimella 201443 
 
CHS 
USA 3143 
Median: 9.8 years 
 
Age: NR 
Male: NR 
White: NR 
DM: NR 
eGFR: NR 
CVD: NR 
C-terminal  
Median: 71 RU/ml (IQR 54-100) 
Ix 201244 
 
CHS 
USA 3107 
Median: 10.5 years  
(IQR: 5.9-11.5) 
Age: 78 (5) 
Male: 40% 
Black: 16% 
DM: 15% 
eGFR: 71 (19) 
CVD: 29%/HF: 9% 
C-terminal 
Median: 70 RU/mL (IQR 53-99) 
Kestenbaum 
201445 
 
MESA 
USA 6547 
Median: 8.5 years  
(IQR: 7.7-8.6) 
Age: 62 
Male: 47% 
White: 39% 
DM: 12% 
eGFR: 84 
(eGFR <60: 16%) 
CVD: 0% 
Intact 
Median: 38 pg/mL (IQR 31-46)  
Mean: 40 pg/mL (SD 15) 
Lutsey 201446 
 
USA 11638 
18.6 years 
Age: 57 
Male: 43% 
DM: 13% 
eGFR: 92 
Intact 
Mean: 44 pg/mL (SD 16) 
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ARIC (max: 20.9) Black: 25% (eGFR <60: 3%) 
CVD: 0% 
Masson 201547 
 
PREDICTOR 
Lazio, Italy 1835 
Mean: 3.8 years 
Age: 73 (5) 
Male: 53% 
White: NR 
DM: 17% 
Creatinine: 1.0 (0.3) 
mg/dL  
CVD: 29% 
C-terminal 
Median: 74 RU/mL (IQR 58-97) 
Panwar 201548 
 
REGARDS 
USA 1551 (615 cases) 
Follow-up: NR 
Age: 65 
Male: 45% 
Black: 40% 
DM: 21% 
eGFR: 86.5 
CVD: 16%  
C-terminal 
Median: 70.5 RU/mL (IQR 53-100) 
Parker 201049 
 
HSS 
San-Francisco, 
USA 
833 
Median: 6.0 years 
Age: 67 (11) 
Male: 81% 
White: 60% 
DM: 27% 
eGFR <60: 22% 
CVD: 100% 
C-terminal 
Median: 43 RU/mL (IQR 29-72) 
Souma 201653 
 
NOMAS 
USA 2525 
Median: 14 years 
Age: 69 (10) 
Male: 36% 
White: 21% 
DM: 21% 
eGFR: 80 (22) 
CVD: NR (No STs) 
C-terminal 
Median: 57 RU/ml (IQR 44-81) 
Speer 201550 
 
 
Saarland, 
Germany 
859 
Median: 2.3 years  
(IQR 0.98-2.93) 
Age: 64  
Male: 69% 
White: NR 
DM: 25% 
Creatinine: 1.2 mg/dL 
(SD 0.8) 
CAD: 43%/HF: 86% 
C-terminal 
Median: 65 RU/mL (IQR 45-115) 
Westerberg 201351 
 
MrOS 
Sweden 2838 
Mean: 4.5 years 
Age: 75.5 (3) 
Male: 100% 
White: NR 
DM: 9% 
eGFR: 72 (20) 
CVD: 19% 
Intact 
Median: 44 pg/mL (IQR 32-58) 
Wright 201452 
 
NOMAS 
USA 2525 
Mean: 12 years 
(SD 5) 
Age: 69 (10) 
Male: 36% 
White: 21% 
On glycemic agents: 
15% 
eGFR: 80 (22) 
CVD: NR (No STs) 
C-terminal 
Median: 57 RU/mL (IQR 44-81) 
Non-dialysed CKD population studies 
Alderson 201560 
 
CRISIS 
Salford, UK 463 
Median: 3.8 years  
(IQR 1.8-5.8) 
Age: 64 (14) 
Male: 62% 
White: 96% 
DM: 31% 
eGFR: 29 (15) 
CVD: 29%/ HF: 18% 
C-terminal 
Median: 209 RU/mL (IQR 128-470) 
Baia 201354 
 
 
Groningen, the 
Netherlands 
593  
Median: 7.0 years  
(IQR 6.2-7.5) 
Age: 52 (12) 
Male: 54% 
White: 95%  
DM: 18% 
eGFR: 47 (16) 
CVD: NR 
C-terminal 
Median: 140 RU/mL (IQR 95-219) 
Bouma-de Krijger 
201423 
 
MASTERPLAN 
The Netherlands 439  
Follow-up: 2 years 
Age: 62 (12) 
Male: 71% 
White: 93% 
DM: 23% 
eGFR: 36 (15) 
CVD: 27% 
C-terminal 
Median: 149 RU/mL (IQR 87-241) 
 
Isakova 201155 USA 3879 Age: 58 (11) DM: 48% C-terminal 
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CRIC 
3.5 years  
(IQR 2.5-4.4) 
Male: 55% 
Black: 42% 
eGFR: 43 (14) 
CAD: 22%/HF: 10% 
Median: 146 RU/mL (IQR 96-239) 
 
Kendrick 201156 
 
HOST 
USA 1099 
Median: 2.9 years 
Mean: 2.8 years 
(SD 1.1) 
Age: 69 (11) 
Male: 98% 
Black: 26% 
DM: 55% 
eGFR: 18 (6) 
CVD: 57% 
C-terminal  
Median: 392 RU/mL (IQR 216-945) 
Levin 201457 
 
CanPREDDICT 
Canada 2402 
1 year 
Age: 68 (13) 
Male: 63% 
White: 89% 
DM: 48% 
eGFR: 28 (9) 
CVD: NR 
C-terminal 
Median: 237 RU/mL (IQR 150-432) 
Munoz-Mendoza 
201761 
 
CRIC 
USA 3875 
Median: 6.9 years 
(IQR 4.2-8.2) 
Age: 58 
Male: 55% 
Black: 42% 
DM: 48% 
eGFR: 44 (15) 
CAD: 22%/HF: 10% 
C-terminal 
Median: 146 RU/mL (IQR 96-239) 
Scialla 201458 
 
CRIC 
USA 3860 
Median: 3.7 years  
(IQR 2.5-4.7) 
Age: 58 (11) 
Male: 55% 
White: 42% 
Black: 41% 
DM: 49% 
eGFR: 44 (15) 
CVD: 31% 
C-terminal 
Median: 146 RU/mL (IQR 96-239) 
Seiler 201459 
 
CARE FOR HOME 
Hamburg, 
Germany 
444 
Median: 2.6 years  
(IQR 1.4-3.6) 
Age: 65 (12) 
Male: 60% 
White: NR 
DM: 38% 
eGFR: 45 (16) 
prevalent CVD: 30% 
C-terminal 
Median: 102 RU/mL (IQR 64-164) 
Dialysis population studies 
Chonchol 201562 
 
HEMO 
USA 1340 
Mean: 2.8 years 
(SD 1.7) 
Age: 57 (14) 
Male: 45% 
Black: 64% 
Hemodialysis: 100% 
DM: 44% 
CVD: 79% 
Intact  
Median: 3118 pg/mL (IQR 726-12928) 
 
Jean 200963 
 
France 219 
2 year survival 
Median: 1.9 years 
Age: 67 (14) 
Male: 57% 
White: NR 
Hemodialysis: 100% 
DM: 35% 
CAD: 19% 
C-terminal 
Median: 2740 RU/mL (IQR 1192-8667) 
Mean: 7060 (SD 13500)  
Kim 201464 South Korea 205 
Mean: 3.5 years 
Age: 47 (14) 
Male: 60% 
White: NR 
Peritoneal Dialysis: 
100% 
DM: 31% 
CAD: 7%/HF: 8% 
C-terminal 
Median: 79 RU/mL (IQR 34-155) 
Moe 201524 
 
EVOLVE 
International 2985 
Median: 4.2 years 
(IQR 1.0-5.0) 
Age: 54 
Male: 59% 
White: 58% 
Hemodialysis: 100% 
DM: 32% 
CVD: 95%/HF: 23% 
Intact (Millipore) 
Median: 5555 pg/mL (Q10-Q90 580-
19540) 
 
Montford 201365 
 
HOST 
USA 654 
Median: 2.9 years 
Age: 60 (11) 
Male: 98% 
White: 38% 
Hemodialysis: 100% 
DM: 41% 
CVD: 52% 
C-terminal 
Median: 4212 RU/mL (IQR 1411-13816) 
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Nowak 201466 
 
 
Germany 239 
Median: 2.5 years 
(IQR: 2.0-2.7) 
Age: 68 (14) 
Male: 64% 
White: NR 
Hemodialysis: 100% 
DM: 38% 
CAD: 31% 
C-terminal 
Mean: 883 RU/mL (SD 1940) 
Olauson 201067 
 
 
Sweden 229 
Median: 1.9 years 
(range: 0.1-5) 
Age: 55 
(IQR 33-68) 
Male: 65% 
White: NR 
Hemodialysis: 41%/ 
PD: 54% 
DM: 34% (as cause of 
ESRD) 
CVD: 41% 
Intact 
Median: 2526 pg/mL  
(Q10-Q90 431-19495) 
 
Scialla 201568 
 
CHOICE 
USA 466 
Median 3.4 years  
(IQR: 1.8-5.9) 
Age: 58 (15) 
Male: 55% 
Black: 36%  
Hemodialysis: 100% 
DM: 57% 
CVD: 56% 
C-terminal 
Median: 1577 RU/mL (IQR 818-4946) 
Age and eGFR are mean (SD). *=approximated from median (IQR) of two mid quartiles. Abbreviations: CAD=coronary artery disease; CKD=chronic kidney 2 
disease; CVD=cardiovascular disease; DM=diabetes mellitus; eGFR=estimated glomerular filtration rate; ESRD=end-stage renal disease; HF=heart failure; 3 
FGF23=fibroblast growth factor-23; IQR=interquartile range; MI=myocardial infarction; NR=not reported; PD=peritoneal dialysis; SD=standard deviation; 4 
ST=stroke; UK=United Kingdom; USA=United States of America. Study acronyms: ARIC=Atherosclerosis Risk in Communities Study; 5 
CanPREDDICT=Canadian study of prediction of death, dialysis and interim cardiovascular events; CARE FOR HOME=Cardiovascular And REnal outcome in 6 
CKD stage 2–4 patients—The FOuRth HOMburg evaluation; CHOICE=Choices for Healthy Outcomes in Caring for ESRD; CHS=The Cardiovascular Health 7 
Study; CRIC=Chronic Renal Insufficiency Cohort; EPIC=European Prospective Investigation into Cancer and Nutrition; EVOLVE=Evaluation of Cinacalcet 8 
Hydrochloride Therapy to Lower Cardiovascular Events; HEMO=The Hemodialysis Study; HOST=Homocysteine in Kidney and End Stage Renal Disease study; 9 
LURIC=Ludwigshafen Risk and Cardiovascular Health study; MASTERPLAN=Multifactorial approach and superior treatment efficacy in renal patients with the 10 
aid of nurse practitioners; MESA=Multi-Ethnic Study of Atherosclerosis; MrOS=multicenter prospective Osteoporotic Fractures in Men study; NOMAS=Stroke-11 
free North Manhattan Study; PIVUS=Prospective Investigation of the Vasculature in Uppsala Seniors study; PREDICTOR=Valutazionedella PREvalenza di 12 
DIsfunzione CardiacaasinTOmatica e di scompensocaRdiaco; REGARDS=Reasons for Geographic and Racial Differences in Stroke; HSS=Heart and Soul 13 
Study; ULSAM=Uppsala Longitudinal Study of Adult Men. 14 
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Figure legends 
 
Figure 1: Study selection flowchart. FGF23=fibroblast growth factor-23; CKD=chronic kidney 
disease. RR=risk ratio. 
 
Figure 2: Association between FGF23 and risk of cardiovascular disease event by population 
type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast growth factor-23. 
Heterogeneity tests across the summary risk ratios for the 3 outcomes: All populations combined 
p=0.23; general populations p=0.59; non-dialysed CKD p=0.75; and dialysis populations p=0.47.  
 
Figure 3: Association between FGF23 and risk of all-cause and cardiovascular mortality by 
population type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast growth 
factor-23. * Number of events not reported for one study. 
 
Figure 4: Association between FGF23 concentration and risk of cause-specific mortality overall 
and by population type. CI=confidence interval; CKD=chronic kidney disease; FGF23=fibroblast 
growth factor-23.  
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